High Dividend Equities: Winning and Losing Stocks for Nov 15thWall St. Cheat SheetThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and p…
CEO on IND status for VGX-100 Open Briefing with CEO & MD Robert Klupacs …4-traders (press release)However, we recognise that dry eye disease is one of the most difficult corneal diseases to develop a treatment for, so we're also working on t…
CSPI Wants St. John's Wort to Carry Warning LabelNatural Products INSIDER… former FDA Commissioner Jane E. Henney warned St. John's wort “interacts with many drugs that are used to treat heart disease, depression, seizures, certain cancers,…
Bristol-Myers Squibb (BMY) Crosses Pivot Point Support at $31.64Financial News Network OnlineThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant reje…
NASDAQ Volume Active Stocks are – ALXN, MDAS, CENX, CRZO, BMRNRetirement Planning… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeuti…
Black Transplant Patients with FSGS Are At Higher RiskRenal and Urology News13% and 14%, respectively), as was the rate of acute rejection (42% vs. 28%, and 31%, respectively). Allograft failure occurred in 27% of AA recipients compared with 16% among …
Bristol-Myers Squibb Earnings In Retrospect: Down 3.6% in the Last 16 Days (BMY)Financial News Network OnlineThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ…
Acute Rejection Risk Higher with Membranous GlomerulonephritisRenal and Urology NewsPHILADELPHIA—Membranous glomerulonephritis (GN) is the most common form of primary GN associated with acute renal allograft rejection following renal transplantation,…
CTAS, ORLY, CIGX, XRAY, ALXN – Notable Stocks with Volume at NASDAQRetirement Planning… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the thera…
Stempeutics receives Rs.3.5 cr DBT fund for phase II trial of IMP for …pharmabiz.comHowever, potential benefits are hampered by many drawbacks such as relative shortage of donors, operative risk, post transplant rejection, recidivism of the pre-exist…